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such as total mesorectal excision, local recurrence rates after
resection were unacceptably high with surgery alone. Phase
III trials were designed to determine the benefit of the addi-
tion of radiotherapy to radical surgery, and these have re-
ported significant reductions in local recurrence.
Two different strategies were evaluated in the preoperative
setting. Initially in Scandinavia the approach of a hypo-frac-
tionated 1-week course of radiotherapy performed prior to
radical surgery was evaluated in a series of phase III trials.
In contrast, the strategy of integrating fluoropyrimidine che-
motherapy with long-course fractionated radiotherapy in
the postoperative setting was then evaluated preoperatively.
Two key trials determined that the addition of fluoropyrimi-
dine to neoadjuvant radiotherapy compared with radiother-
apy alone significantly reduced the risk of local recurrence.
Following the increasing use of total mesorectal excision
and the associated lower rates of local recurrence, in the
Netherlands and in the United Kingdom (UK) two phase III tri-
als were conducted. The Dutch TME and MRC CR07 trials
showed a reduction in local recurrence from the addition of
short-course preoperative radiotherapy but without any im-
pact on overall survival.
The two strategies (short-course and long-course treat-
ment) have developed in parallel. This leads to a number of
questions:
• When preoperative radiotherapy is combined with radical
surgery to reduce the risk of local recurrence, is there any
difference in the efficacy of the two approaches?
• Is there any difference in the acute toxicity of the two
approaches?
• Is there any difference in the late toxicity between the two
approaches?
Two phase III trials have directly compared short-course
preoperative radiotherapy followed by immediate surgery ver-
sus long-course concurrent chemoradiotherapy followed by a
delay in surgery. The Polish trial was designed to determinewhether long-course chemoradiotherapy would increase the
chance of sphincter preservation, whereas the TROG trial
was designed to compare local recurrence rates between the
two approaches.
Given the relatively low rates of local recurrence seen in
routine clinical practice and within the trials, both studies
are underpowered for a formal comparison of efficacy. How-
ever, neither trial has reported a significant difference in local
recurrence between the two approaches.
With respect to acute toxicity, long-course chemoradio-
therapy is associated with the concomitant administration
of fluoropyrimidine chemotherapy. The acute toxicity is high-
er with this approach compared with short-course hypo-frac-
tionated radiotherapy. In terms of long-term toxicity, neither
the Polish nor the TROG trials have reported any evidence of
any significant difference in late toxicity between the two
approaches.
The trials that have compared these two approaches have
focused on the neoadjuvant use of radiotherapy combined
with radical surgery. The current evidence does not suggest
any major differences in efficacy and long-term outcome in
patients with resectable disease. However, where the margin
of excision is threatened or involved, current consensus is
that long-course chemoradiotherapy is the preferred ap-
proach. There are limited non-randomised studies that have
reported the use of short-course preoperative radiotherapy
followed by an elective delay to surgery from both Sweden
and Leeds. There are also comparative interim data from
the Stockholm III trial. Short-course preoperative radiother-
apy followed by an elective delay to surgery is a treatment op-
tion that could be considered in patients who are considered
unsuitable for concurrent chemoradiotherapy.
The use of these two radiotherapy strategies needs to be
considered within the changing landscape of rectal cancer
management. There is increasing interest in organ-preserving
approaches where surgery is deferred or avoided. In this
context dose escalation of the radiation dose is likely to
increase the complete response rates. This approach is more
easily and safely obtained by dose-escalating long-course
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course radiotherapy should be approached with caution and
within the context of a clinical trial. The efficacy of short-
course radiotherapy and delay in early rectal cancer is the
subject of an ongoing study within the UK (TREC). The Dutch
CARTS study has evaluated chemoradiotherapy followed by
local excision.
A further area of interest is the use of neoadjuvant chemo-
therapy that is integrated closely with neoadjuvant radiother-
apy. In this context the use of short-course radiotherapy may
have some advantages and needs to be tested in clinical trials.
This will be illustrated by discussion of both the European
RAPIDO and the North American PROSPECT trials.
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